Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication

Table 1 Demographic and clinical data at baseline (intention-to-treat population) n (%)

	MBST	Hybrid	P value
Included in ITT analysis	140	144	-
Age, mean ± SD (yr)	58.9 ± 12.8	58.8 ± 11.9	0.922
Gender (male)	58 (41.4)	72 (50.0)	0.155
Current smoker	8 (5.7)	9 (6.3)	0.849
Alcohol drinking	18 (12.9)	15 (10.4)	0.581
Diabetes	7 (5.0)	6 (4.2)	0.783
Hypertension	27 (19.3)	20 (13.9)	0.264
Previous history of peptic ulcer	19 (13.6)	18 (12.5)	0.537
Endoscopic diagnosis			0.783
HPAG	117 (83.6)	136 (94.4)
Gastric ulcer	8 (5.7)	6 (4.2)
Duodenal ulcer	5 (3.6)	0 (0.0)
Gastric and duodenal ulcer	2 (1.4)	2 (1.4)
Adenoma	8 (5.7)	0 (0.0)
Positive CLO test	106 (75.7)	116 (80.6)	0.389
H. pylori colonization			0.234
Negative	7 (5.0)	13 (9.0)
Mild	66 (47.1)	65 (45.1)
Moderate	52 (37.1)	43 (29.9)
Marked	15 (10.7)	23 (16.0)
Atrophic change	11 (7.8)	14 (9.8)	0.122
Intestinal metaplasia	10 (7.2)	16 (11.1)	0.239
Drop out	4 (2.8)	6 (4.1)	0.285
Noncompliance	0 (0.0)	0 (0.0)
Follow-up loss	4 (2.8)	6 (4.1)
Discontinued therapy	0 (0.0)	0 (0.0)
due to adverse events

MBST: 14-d moxifloxacin-based sequential therapy; Hybrid: 14-d hybrid therapy; ITT: Intention-to-treat; HPAG: Helicobacter pylori associated gastritis; CLO test: Rapid urease test; H. pylori: Helicobacter pylori.

Table 2 Helicobacter pylori eradication rates

	MBST	Hybrid	P value
ITT analysis
Eradication rate	91.4% (128/140)	79.2% (114/144)	0.013
95%CI	90.2%-92.9%	77.3%-80.7%
PP analysis
Eradication rate	94.1% (128/136)	82.6% (114/138)	0.003
95%CI	92.9%-95.6%	80.6%-84.1%

ITT: Intention-to-treat; PP: Per-protocol; MBST: 14-d moxifloxacin-based sequential therapy; Hybrid: 14-d hybrid therapy.

Table 3 Adverse events and compliance n (%)

	MBST	Hybrid	P value
Adverse events	(n = 136)	(n = 138)
Bloating/dyspepsia	4 (2.9)	5 (3.6)
Taste distortion	4 (2.9)	4 (2.9)
Epigastric discomfort	4 (2.9)	7 (5.1)
Nausea	2 (1.5)	4 (2.9)
Abdominal pain	0 (0.0)	0 (0.0)
Diarrhea	2 (1.5)	7 (5.1)
Total	16 (11.8)	27 (19.6)	0.019
Compliance	136 (100.0)	138 (100.0)

MBST: 14-d moxifloxacin-based sequential therapy; Hybrid: 14-d hybrid therapy.